Quick Answer
ADMA BIOLOGICS, INC. reported Diluted EPS of $0.60 per share for fiscal year 2025.
ADMA BIOLOGICS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | $0.60 | -25.9% |
| 2024 | $0.81 | +723.1% |
| 2023 | -$0.13 | +60.6% |
| 2022 | -$0.33 | +35.3% |
| 2021 | -$0.51 | +42.0% |
| 2020 | -$0.88 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.15 | +0.0% | +7.1% |
| June 30, 2025 | $0.14 | +7.7% | +27.3% |
| March 31, 2025 | $0.11 | +37.5% | -26.7% |
| September 30, 2024 | $0.15 | +1400.0% | +15.4% |
| June 30, 2024 | $0.13 | +533.3% | +62.5% |
| March 31, 2024 | $0.08 | +366.7% | +700.0% |
| September 30, 2023 | $0.01 | +112.5% | +133.3% |
| June 30, 2023 | -$0.03 | +57.1% | +0.0% |
- ADMA BIOLOGICS, INC. showed a decrease of -25.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, ADMA BIOLOGICS, INC.’s diluted eps has grown by 168.2% (from $0.88 per share (loss) to $0.60 per share).
- The most recent figure is from ADMA BIOLOGICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: